Connection
Maurizio Zangari to Fusion Proteins, bcr-abl
This is a "connection" page, showing publications Maurizio Zangari has written about Fusion Proteins, bcr-abl.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.014 |
|
|
|
-
Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr 15; 97(8):1920-8.
Score: 0.014